SAN FRANCISCO, July 7, 2015 /PRNewswire/ - goBalto, Inc., the leading provider of cloud-based clinical study startup solutions, announced today its latest version of goBalto Activate. The second major release of 2015 offers new features that further accelerate clinical study startup.
"There is intense pressure to speed clinical trials and restrain costs, with Sponsors and CROs continuing to search for ways to automate and reduce the time it takes to get investigative sites up and running," said Sujay Jadhav, goBalto's CEO. "goBalto is the industry standard for study startup, completing the eClinical Stack with full integration to existing CTMS and eTMF systems, enabling business process optimization, oversight and continual process improvements that existing systems don't address."
"The clinical trials industry recognizes that study startup is one of the most difficult areas today resulting in delays and high costs. Our initial research in this area shows that the study startup process is very unsophisticated and inefficient," said Ken Getz, Director, Tufts Center for the Study of Drug Development. "Sponsor organizations are typically struggling to identify and engage a global community of investigative sites quickly; to review and approve regulatory documentation in a timely manner; to manage costs, resources and timelines."
With over 2,000 pharmaceutical and CRO users in more than 60 countries using Activate to manage, track, and complete study startup tasks, goBalto has the largest industry-proven set of country workflows. Our standard 'out-of-the-box' country specific regulatory business process workflows allow quick site activation, leading to greater cost savings and faster market entry, making valuable therapies available to patients sooner.
"This release illustrates our commitment to our customers as we continue to support them accelerate the development of drugs that save lives and improve the quality of life," said Jadhav. "We now service three of the top 5 CROs and more than two-thirds of the top 20 pharma's, managing their clinical trial documents globally."
Activate customers report improved business performance and a reduction in cycle times by > 30%. New capabilities just released aim to improve project management capabilities and usability, with a focus on enhanced risk management, utilization, business process improvement, and administration. Activate's new features include:
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.